T-cell vaccines that elicit effective immune responses against HCV in chimpanzees may create greater immune pressure for viral mutation

Vaccine

Volumn 27, Issue 19, 2009, Pages 2594-2602

  Zubkova, I ^a   Choi, Y H ^b   Chang, E ^c   Pirollo, K ^c   Uren, T ^a   Watanabe, H ^a   Wells, F ^a   Kachko, A ^a   Krawczynski, K ^b   Major, M E ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

Author keywords

Chimpanzee; Hepatitis C virus; Immune escape; T cell

Indexed keywords

ADENOVIRUS VECTOR; CD3 ANTIGEN; GAMMA INTERFERON; IMMUNOLIPOSOME; INTERLEUKIN 12; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 5B; PLASMID AG410; PLASMID DNA; PLASMID INTERLEUKIN 12; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIGEN PRESENTING CELL; ARTICLE; CHIMPANZEE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; IMMUNE ESCAPE; IMMUNIZATION; IMMUNOSURVEILLANCE; LIPOSOMAL GENE DELIVERY SYSTEM; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; SEQUENCE ANALYSIS; STATISTICAL ANALYSIS; VACCINIA VIRUS; VIRUS INHIBITION; VIRUS MUTATION; VIRUS NEUTRALIZATION; VIRUS RECOMBINANT; VIRUS REPLICATION;

ADENOVIRIDAE; AMINO ACID SUBSTITUTION; ANIMALS; FEMALE; GENETIC VECTORS; HEPACIVIRUS; HEPATITIS C; IMMUNIZATION, SECONDARY; LIPOSOMES; LIVER; MICE; MUTATION, MISSENSE; OVARY; PAN TROGLODYTES; T-LYMPHOCYTES; VACCINES, DNA; VIRAL HEPATITIS VACCINES; VIRAL NONSTRUCTURAL PROTEINS;

EID: 63449109294     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.02.045     Document Type: Article

References (56)

1. Alter M.J., Kruszon-Moran D., Nainan O.V., McQuillan G.M., Gao F., Moyer L.A., et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 341 8 (1999) 556-562
2. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 9286 (2001) 958-965
3. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales Jr. F.L., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 13 (2002) 975-982
4. Farci P., Shimoda A., Coiana A., Diaz G., Peddis G., Melpolder J.C., et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 288 5464 (2000) 339-344
5. Erickson A.L., Kimura Y., Igarashi S., Eichelberger J., Houghton M., Sidney J., et al. The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity 15 December (6) (2001) 883-895
6. Ward S., Lauer G., Isba R., Walker B., and Klenerman P. Cellular immune responses against hepatitis C virus: the evidence base 2002. Clin Exp Immunol 128 2 (2002) 195-203
7. Farci P., Alter H.J., Wong D.C., Miller R.H., Govindarajan S., Engle R., et al. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci USA 91 (1994) 7792-7796
8. Krawczynski K., Alter M.J., Tankersley D.L., Beach M., Robertson B.H., Lambert S., et al. Effect of immune globulin on the prevention of experimental hepatitis C virus infection. J Infect Dis 173 4 (1996) 822-828
9. Yu M.Y., Bartosch B., Zhang P., Guo Z.P., Renzi P.M., Shen L.M., et al. Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma. Proc Natl Acad Sci USA 101 20 (2004) 7705-7710
10. Zhang P., Wu C.G., Mihalik K., Virata-Theimer M.L., Yu M.Y., Alter H.J., et al. Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma. Proc Natl Acad Sci USA 104 20 (2007) 8449-8454
11. Choo Q.L., Kuo G., Ralston R., Weiner A., Chien D., Van Nest G., et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci USA 91 4 (1994) 1294-1298 (JID - 7505876)
12. Forns X., Payette P.J., Ma X., Satterfield W., Eder G., Mushahwar I.K., et al. Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV. Hepatology 32 3 (2000) 618-625
13. Puig M., Major M.E., Mihalik K., Yu M.Y., and Feinstone S.M. Immunization of chimpanzees with an envelope protein-based vaccine enhances specific humoral and cellular immune responses that delay hepatitis C virus infection. Vaccine 22 (2004) 991-1000
14. Prince A.M., Brotman B., Lee D.H., Ren L., Moore B.S., and Scheffel J.W. Significance of the anti-E2 response in self-limited and chronic hepatitis C virus infections in chimpanzees and in humans. J Infect Dis 180 4 (1999) 987-991
15. Bartosch B., Bukh J., Meunier J.C., Granier C., Engle R.E., Blackwelder W.C., et al. In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc Natl Acad Sci USA 100 24 (2003) 14199-14204
16. Logvinoff C., Major M.E., Oldach D., Heyward S., Talal A., Balfe P., et al. Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci USA 101 27 (2004) 10149-10154
17. Pestka J.M., Zeisel M.B., Blaser E., Schurmann P., Bartosch B., Cosset F.L., et al. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci USA 104 14 (2007) 6025-6030
18. Diepolder H.M., Gerlach J.T., Zachoval R., Hoffmann R.M., Jung M.C., Wierenga E.A., et al. Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J Virol 71 8 (1997) 6011-6019
19. Gerlach J.T., Diepolder H.M., Jung M.C., Gruener N.H., Schraut W.W., Zachoval R., et al. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology 117 4 (1999) 933-941
20. Grüner N.H., Gerlach T.J., Jung M.C., Diepolder H.M., Schirren C.A., Schraut W.W., et al. Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C. J Infect Dis 181 5 (2000) 1528-1536
21. Lechner F., Wong D.K., Dunbar P.R., Chapman R., Chung R.T., Dohrenwend P., et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 191 9 (2000) 1499-1512
22. Thimme R., Oldach D., Chang K.M., Steiger C., Ray S.C., and Chisari F.V. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 194 10 (2001) 1395-1406
23. Cooper S., Erickson A.L., Adams E.J., Kansopon J., Weiner A.J., Chien D.Y., et al. Analysis of a successful immune response against hepatitis C virus. Immunity 10 4 (1999) 439-449
24. Thimme R., Bukh J., Spangenberg H.C., Wieland S., Pemberton J., Steiger C., et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci USA 99 24 (2002) 15661-15668
25. Grakoui A., Shoukry N.H., Woollard D.J., Han J.H., Hanson H.L., Ghrayeb J., et al. HCV persistence and immune evasion in the absence of memory T cell help. Science 302 5645 (2003) 659-662
26. Nascimbeni M., Mizukoshi E., Bosmann M., Major M.E., Mihalik K., Rice C.M., et al. Kinetics of CD4+ and CD8+ memory T-cell responses during hepatitis C virus rechallenge of previously recovered chimpanzees. J Virol 77 8 (2003) 4781-4793
27. Shoukry N.H., Grakoui A., Houghton M., Chien D.Y., Ghrayeb J., Reimann K.A., et al. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med 197 12 (2003) 1645-1655
28. Takaki A., Wiese M., Maertens G., Depla E., Seifert U., Liebetrau A., et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 6 5 (2000) 578-582
29. Lanford R.E., and Bigger C. Advances in model systems for hepatitis C virus research. Virology 293 1 (2002) 1-9
30. Rollier C., Depla E., Drexhage J.A., Verschoor E.J., Verstrepen B.E., Fatmi A., et al. Control of heterologous hepatitis C virus infection in chimpanzees is associated with the quality of vaccine-induced peripheral T-helper immune response. J Virol 78 1 (2004) 187-196
31. Youn J.W., Park S.H., Lavillette D., Cosset F.L., Yang S.H., Lee C.G., et al. Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in the chimpanzee. Hepatology 42 6 (2005) 1429-1436
32. Puig M., Mihalik K., Tilton J.C., Williams O., Merchlinsky M., Connors M., et al. CD4+ immune escape and subsequent T-cell failure following chimpanzee immunization against hepatitis C virus. Hepatology 44 3 (2006) 736-745
33. Folgori A., Capone S., Ruggeri L., Meola A., Sporeno E., Ercole B.B., et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med 12 2 (2006) 190-197
34. Elmowalid G.A., Qiao M., Jeong S.H., Borg B.B., Baumert T.F., Sapp R.K., et al. Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proc Natl Acad Sci USA 104 20 (2007) 8427-8432
35. Major M.E., Mihalik K., Puig M., Rehermann B., Nascimbeni M., Rice C.M., et al. Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge. J Virol 76 13 (2002) 6586-6595
36. Weiner A.J., Paliard X., Selby M.J., Medina-Selby A., Coit D., Nguyen S., et al. Intrahepatic genetic inoculation of hepatitis C virus RNA confers cross-protective immunity. J Virol 75 15 (2001) 7142-7148
37. Bassett S.E., Guerra B., Brasky K., Miskovsky E., Houghton M., Klimpel G.R., et al. Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. Hepatology 33 6 (2001) 1479-1487
38. Mehta S.H., Cox A., Hoover D.R., Wang X.H., Mao Q., Ray S., et al. Protection against persistence of hepatitis C. Lancet 359 9316 (2002) 1478-1483
39. Jechlinger W. Optimization and delivery of plasmid DNA for vaccination. Expert Rev Vaccines 5 6 (2006) 803-825
40. Cristiano R.J., and Curiel D.T. Strategies to accomplish gene delivery via the receptor-mediated endocytosis pathway. Cancer Gene Ther 3 1 (1996) 49-57
41. Cheng P.W. Receptor ligand-facilitated gene transfer: enhancement of liposome-mediated gene transfer and expression by transferrin. Hum Gene Ther 7 3 (1996) 275-282
42. Yu W., Pirollo K.F., Yu B., Rait A., Xiang L., Huang W., et al. Enhanced transfection efficiency of a systemically delivered tumor-targeting immunolipoplex by inclusion of a pH-sensitive histidylated oligolysine peptide. Nucleic Acids Res 32 5 (2004) e48
43. Xu L., Tang W.H., Huang C.C., Alexander W., Xiang L.M., Pirollo K.F., et al. Systemic p53 gene therapy of cancer with immunolipoplexes targeted by anti-transferrin receptor scFv. Mol Med 7 10 (2001) 723-734
44. Xu L., Huang C.C., Huang W., Tang W.H., Rait A., Yin Y.Z., et al. Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. Mol Cancer Ther 1 5 (2002) 337-346
45. Pasquier B., Lepelletier Y., Baude C., Hermine O., and Monteiro R.C. Differential expression and function of IgA receptors (CD89 and CD71) during maturation of dendritic cells. J Leukoc Biol 76 6 (2004) 1134-1141
46. Grunebach F., Muller M.R., Nencioni A., and Brossart P. Delivery of tumor-derived RNA for the induction of cytotoxic T-lymphocytes. Gene Ther 10 5 (2003) 367-374
47. Wolf S.F., Temple P.A., Kobayashi M., Young D., Dicig M., Lowe L., et al. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J Immunol 146 9 (1991) 3074-3081
48. Choi Y.H., and Hagedorn C.H. Purifying mRNAs with a high-affinity eIF4E mutant identifies the short 3′ poly(A) end phenotype. Proc Natl Acad Sci USA 100 12 (2003) 7033-7038
49. Major M.E., Mihalik K., Fernandez J., Seidman J., Kleiner D., Kolykhalov A.A., et al. Long-term follow-up of chimpanzees inoculated with the first infectious clone for hepatitis C virus. J Virol 73 4 (1999) 3317-3325
50. Wedemeyer H., Gagneten S., Davis A., Bartenschlager R., Feinstone S., and Rehermann B. Oral immunization with HCV-NS3-transformed Salmonella: induction of HCV-specific CTL in a transgenic mouse model. Gastroenterology 121 5 (2001) 1158-1166
51. Major M.E., Dahari H., Mihalik K., Puig M., Rice C.M., Neumann A.U., et al. Hepatitis C virus kinetics and host responses associated with disease and outcome of infection in chimpanzees. Hepatology 39 6 (2004) 1709-1720
52. Fernandez J., Taylor D., Morhardt D.R., Mihalik K., Puig M., Rice C.M., et al. Long-term persistence of infection in chimpanzees inoculated with an infectious hepatitis C virus clone is associated with a decrease in the viral amino acid substitution rate and low levels of heterogeneity. J Virol 78 18 (2004) 9782-9789
53. Ray S.C., Mao Q., Lanford R.E., Bassett S., Laeyendecker O., Wang Y.M., et al. Hypervariable region 1 sequence stability during hepatitis C virus replication in chimpanzees. J Virol 74 7 (2000) 3058-3066
54. Ray S.C., Fanning L., Wang X.H., Netski D.M., Kenny-Walsh E., and Thomas D.L. Divergent and convergent evolution after a common-source outbreak of hepatitis C virus. J Exp Med 201 11 (2005) 1753-1759
55. Lavillette D., Morice Y., Germanidis G., Donot P., Soulier A., Pagkalos E., et al. Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. J Virol 79 10 (2005) 6023-6034
56. Kimura Y., Gushima T., Rawale S., Kaumaya P., and Walker C.M. Escape mutations alter proteasome processing of major histocompatibility complex class I-restricted epitopes in persistent hepatitis C virus infection. J Virol 79 8 (2005) 4870-4876